15 jun: Fredagens aktier: Cyklisk fremgang inden afgørende græsk valg
18 jun: USA/aktier: Græsk valg sender futures højere
15-06-2012 23:53:00

Merck Loses Nasonex Patent Suit; Says Likely to Appeal

Relateret indhold

By Ben Fox Rubin

Drug maker Merck & Co. (MRK) said a U.S. district court ruled against it in a patent-infringement suit involving Apotex Inc.

In 2009, Merck filed the suit in New Jersey in an effort to block Apotex, a Canadian generic drug manufacturer, from selling a generic copy of Merck's blockbuster allergy drug Nasonex before U.S. patent protection expires.

Apotex had challenged the validity of the U.S. patent covering Nasonex. Merck said its patent for Nasonex is due to expire in 2018.

Bruce N. Kuhlik, Merck's general counsel, said his company was pleased the court ruled that its patent on Nasonex is valid, but was disappointed the court said the patent wasn't infringed by Apotex's product.

"Today's decision reflects just one step in the lengthy patent litigation process, and we plan to review all of our options, including a likely appeal of the decision," Mr. Kuhlik said.

Merck, like its rivals, has been cutting costs as part of an effort to soften the hit from increased generic competition. The company's top-selling allergy and asthma medication Singulair loses patent exclusivity in August and the ripple-effect from generic versions of rival Pfizer Inc.'s (PFE) cholesterol fighter Lipitor have contributed to a decline in sales of Merck's anticholesterol drug Vytorin.

In April, Merck said its first-quarter earnings rose 67% as the drug maker's cost controls helped offset slower-than-expected sales growth.

Shares closed Friday at $38.94 and were down 14 cents after hours. The stock is up 3.3% year-to-date.

Write to Ben Fox Rubin at ben.rubin@dowjones.com

(END) Dow Jones Newswires

June 15, 2012 17:53 ET (21:53 GMT)

Copyright (c) 2012 Dow Jones & Company, Inc.

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Fondsbørsmeddelelser

Carlsberg: Russisk ølproduktion fortsætter i bakgear

22-05-2015 16:33:25
Carlsberg og de øvrige bryggerier på det russiske ølmarked fortsætter med at holde igen med ølbrygningen i landet. Således faldt ølproduktionen i Rusland med 7,..

Novo: Ny fusion styrker købersiden ved forhandlingsbordet

22-05-2015 14:15:45
Medicinalselskaberne kan formentlig se frem til endnu sværere prisforhandlinger fremover i USA. Modparterne ved forhandlingsbordet, de såkaldte Pharma Benefit M..

Aktier/åbning: Zealand i rødt efter regnskab

22-05-2015 09:18:44
Det danske C20 Cap-indekset starter med bevægelser fra side til side i niveauet 1.016 fredag morgen på en dag, hvor Zealand Pharma - uden for eliteindekset - er..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Novo: Ny fusion styrker købersiden ved forhandlingsbordet
2
Novo/Sydbank: Solide diabetes-resultater i Saxenda-studie - NY
3
Siemens-vindchef: Meget travlt i 2015 og omtimisme om 2016
4
Anklager kræver to års fængsel til Don Ø i Parken-sag - NY
5
Novo: Saxenda mindsker risiko for udvikling af diabetes - NY

Relaterede aktiekurser

Merck & Co., Inc 59,38 -1,2% Fald i aktiekurs
Merck AND CO Inc 53,77 -0,9% Fald i aktiekurs

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2015  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
23. maj 2015 15:23:46
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20150519.1 - EUROWEB1 - 2015-05-23 15:23:46 - 2015-05-23 15:23:46 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x